Among various adverse events, hyperkalemia has always been the major concerning, as the use of ns-MRAs could lead to decreased potassium excretion due to the blockade of aldosterone receptors, resulting in an elevated level of serum potassium (54). The gene discussed is NR3C2; the disease is Hyperkalemia.